Leucine 7 to Proline 7 Polymorphism in the Preproneuropeptide Y Is Associated with Proteinuria, Coronary Heart Disease, and Glycemic Control in Type 1 Diabetic Patients

Diabetes Care

Volumn 27, Issue 2, 2004, Pages 503-509

  Pettersson Fernholm, Kim ^a,b   Karvonen, Matti K ^c   Kallio, Jaana ^c   Forsblom, Carol M ^a,b   Koulu, Markku ^c   Pesonen, Ullamari ^c   Fagerudd, Johan A ^a,b   Groop, Per Henrik ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; LEUCINE; NEUROPEPTIDE Y; PREPRONEUROPEPTIDE Y; PROLINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; FINLAND; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEINURIA; REGRESSION ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEUCINE; MALE; MUTATION, MISSENSE; NEUROPEPTIDE Y; PROLINE; PROTEIN PRECURSORS; PROTEINURIA; RISK FACTORS; TRIGLYCERIDES;

EID: 0842268335     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.2.503     Document Type: Article

References (28)

1. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945, 1996
2. Bischoff A, Michel MC: Renal effects of neuropeptide Y. Pflugers Arch 435:443-453, 1998
3. Playford RJ, Mehta S, Upton P, Rentch R, Moss S, Calam J, Bloom S, Payne N, Ghatei M, Edwards R: Effect of peptide YY on human renal function. Am J Physiol 2687:F754-F759, 1995
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
5. von Heijne G: The signal peptide. J Membr Biol 115:195-201, 1990
6. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT: Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 159:145-151, 2001
7. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MI: Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 4:1434-1437, 1998
8. Karvonen MK, Koulu M, Pesonen U, Uusitupa, MI, Tammi A, Viikari J, Simell O, Ronnemaa T: Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children. J Clin Endocrinol Metab 85:1455-1460, 2000
9. Niskanen L, Karvonen MK, Valve R, Uusitupa MI, Tammi A, Viikari J, Simell O, Ronnemaa T: Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 85:2266-2269, 2000
10. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, Laakso M, Uusitupa MI, Koulu M: Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 108:235-236, 2000
11. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ: Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626-632, 2000
12. Pettersson-Fernholm K, Forsblom C, Perola M, Groop PH: Polymorphisms in the nephrin gene and diabetic nephropathy in type 1 diabetic patients. Kidney Int 63:1205-1210, 2003
13. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen CJ, Uusitupa MI, Koulu M: Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 15:1242-1244, 2001
14. Kallio J, Pesonen U, Karvonen MK, Kojima M, Hosoda H, Kangawa K, Koulu M: Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. J Clin Endocrinol Metab 86:5348-5352, 2001
15. Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M: Changes in diurnal sympatho-adrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-NPY. J Clin Endocrinol Metab 88: 3278-3283, 2003
16. Satoh C, Satoh F, Takahasi K, Murakami O, Sone M, Totsune K, Yabe T, Ohneda M, Fukuda M, Sugimura K, Ogawa S, Nagakubo I, Sato T, Mouri T: Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. Endocr J 46:139-146, 1999
17. Groop PH, Elliott T, Ekstrand A, Franssila-Kallunki A, Friedman R, Viberti GC, Taskinen MR: Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 45:974-979, 1996
18. Pernow J, Lundberg JM, Kaijser L: Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci 40:47-54, 1987
19. Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U, Kallio J, Uusitupa M, Laakso M: The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism 52:643-646, 2003
20. Carpentier A, Patterson BW, Leung N, Lewis GF: Sensitivity to acute insulin-mediated suppression of plasma free fatty acid is not a determinant of fasting VLDL triglyceride secretion in healthy humans. Diabetes 51:1867-1875, 2002
21. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS: Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 266:R1765-R1770, 1994
22. Schwab US, Agren JJ, Valve R, Hallikainen MA, Sarkkinen ES, Jauhiainen M, Karvonen MK, Pesonen U, Koulu M, Uusitupa MI, Savolainen MJ: The impact of the leucine 7 to proline 7 polymorphism of the neuropeptide Y gene on postprandial lipemia and on the response of serum total and lipoprotein lipids to a reduced fat diet. Eur J Clin Nutr 56:149-156, 2002
23. Landau D, Israel E, Rivkis I, Kachko L, Schrijvers BF, Flyvbjerg A, Phillip M, Segev Y: The effect of growth hormone on the development of diabetic kidney disease in rats. Nephrol Dial Transplant 18: 694-702, 2003
24. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H: Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 75-76:231-238, 1998
25. Michel MC, Gaida W, Beck-Sickinger AG: Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy. Mol Pharmacol 42:642-648, 1992
26. Echtenkamp SF, Dandridge PF: Influence of renal sympathetic nerve stimulation on renal function in the primate. Am J Physiol 257:F204-F209, 1989
27. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski A: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293, 2003
28. Perola M, Sajantila A, Sarti C, Stengard J, Tamminen M, Puska P, Huttunen J, Tuomilehto J, Peltonen L: Angiotensin-converting enzyme genotypes in the high- and low-risk area for coronary heart disease in Finland. Genet Epidemiol 12:391-399, 1995